# Research on the Correlation Between Organoid Drug Sensitivity Testing and Precise Treatment of Gastrointestinal Tumors

> **NCT06332716** · PHASE3 · UNKNOWN · sponsor: **Jianjun Yang,MD** · enrollment: 68 (estimated)

## Conditions studied

- Gastrointestinal Tumors，3D Organoids，Drug Sensitivity

## Interventions

- **OTHER:** Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.

## Key facts

- **NCT ID:** NCT06332716
- **Lead sponsor:** Jianjun Yang,MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-26
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332716, "Research on the Correlation Between Organoid Drug Sensitivity Testing and Precise Treatment of Gastrointestinal Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06332716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*